Yes, patients with cardiomyopathy typically have elevated BNP levels.
BNP is elevated in cardiomyopathy due to increased ventricular wall stress and myocardial stretch, making it a valuable diagnostic and prognostic biomarker across different cardiomyopathy subtypes. 1
Mechanism of BNP Elevation in Cardiomyopathy
BNP is released from cardiac myocytes in response to:
- Increased left ventricular end-diastolic wall stress
- Myocardial stretch and tension
- Direct myocyte damage (particularly in infiltrative cardiomyopathies)
- Elevated ventricular filling pressures
The degree of elevation varies by cardiomyopathy type and severity 1, 2.
BNP Levels by Cardiomyopathy Type
Hypertrophic Cardiomyopathy (HCM)
- BNP is consistently elevated and predicts adverse outcomes 3, 4
- In a large cohort of 772 HCM patients, BNP was an independent predictor of mortality with 3-year survival decreasing across tertiles: 99.2% (BNP ≤98 pg/mL), 94.8% (BNP 98-298 pg/mL), and 89.9% (BNP ≥298 pg/mL) 3
- Patients with persistently elevated BNP >100 pg/mL had significantly worse 5-year outcomes 4
- Even in apical HCM, elevated BNP (≥226 pg/mL) independently predicted adverse events with a hazard ratio of 3.71 5
Ischemic Cardiomyopathy
- BNP levels are significantly higher in ischemic compared to dilated cardiomyopathy (776 ± 91 vs. 532 ± 85 pg/mL, p<0.05) 6
- Elevated BNP correlates with myocardial scar burden, LV cavity size, reduced ejection fraction, and increased wall stress 7
- The higher BNP in ischemic etiology reflects both hemodynamic stress and ongoing myocardial injury
Infiltrative Cardiomyopathy (Cardiac Amyloidosis)
- BNP is elevated even without clinical heart failure or increased wall stress 2
- Sensitivity of 93% and specificity of 90% for detecting cardiac involvement 2
- Elevation occurs from both elevated filling pressures AND direct myocyte damage from amyloid deposits
- BNP predicts future cardiac involvement and mortality in amyloidosis patients 2
Diagnostic Thresholds
For ruling out heart failure in cardiomyopathy patients:
- BNP <100 pg/mL has 90% sensitivity for excluding HF 1
- NT-proBNP <300 pg/mL effectively rules out HF 1
For supporting HF diagnosis:
- BNP >400 pg/mL suggests HF 1
- NT-proBNP age-adjusted cutoffs: <50 years: 450 pg/mL; 50-75 years: 900 pg/mL; >75 years: 1800 pg/mL 1
Important Caveats
BNP may be falsely low in:
- Obesity - the most significant confounder, with BNP decreasing as BMI increases 1
- Flash pulmonary edema (initially, but rises over time) 1
BNP may be higher than expected in:
- Atrial fibrillation
- Renal dysfunction
- Pulmonary hypertension or embolism
- Advanced age
- Female sex 1
These confounders don't represent false positives but rather additional sources of ventricular stress requiring careful clinical interpretation 1.
Clinical Application
Measurement of BNP is useful to support clinical judgment for diagnosing cardiomyopathy-related heart failure, especially when clinical uncertainty exists 1. The biomarker provides:
- Diagnostic confirmation when cardiomyopathy is suspected
- Risk stratification for adverse outcomes
- Prognostic information independent of imaging findings
- Monitoring of disease progression and treatment response
In patients with established cardiomyopathy, serial BNP measurements add incremental prognostic value beyond baseline levels alone 4.